The emerging role of zinc transporters in cellular homeostasis and cancer by Bafaro, Elizabeth et al.
OPEN
REVIEW
The emerging role of zinc transporters in cellular homeostasis
and cancer
Elizabeth Bafaro1, Yuting Liu1, Yan Xu2 and Robert E Dempski1
Zinc is an essential micronutrient that plays a role in the structural or enzymatic functions of many cellular proteins. Cellular zinc
homeostasis involves the opposing action of two families of metal transporters: the ZnT (SLC30) family that functions to reduce
cytoplasmic zinc concentrations and the ZIP (SLC39) family that functions to increase cytoplasmic zinc concentrations. Fluctuations
in intracellular zinc levels mediated by these transporter families affect signaling pathways involved in normal cell development,
growth, differentiation and death. Consequently, changes in zinc transporter localization and function resulting in zinc
dyshomeostasis have pathophysiological effects. Zinc dyshomeostasis has been implicated in the progression of cancer. Here we
review recent progress toward understanding the structural basis for zinc transport by ZnT and ZIP family proteins, as well as
highlight the roles of zinc as a signaling molecule in physiological conditions and in various cancers. As zinc is emerging as an
important signaling molecule in the development and progression of cancer, the ZnT and ZIP transporters that regulate cellular zinc
homeostasis are promising candidates for targeted cancer therapy.
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INTRODUCTION
Zinc is the second most abundant transition metal in the human
body. Within a cell, zinc is redox-inert and has a valence state of
+2. Zinc is maintained in the Zn2+ state under all biologically
relevant redox potentials and pH conditions.1 Zinc shows ﬂexible
and dynamic coordination geometry with nitrogen, oxygen and
sulfur ligands present in histidine, glutamate, aspartate and
cysteine residues in proteins.1 Thus, the chemical properties of
zinc are ideal for its many biological roles.
The essentiality of zinc as a trace nutrient was ﬁrst discovered in
the fungus Aspergillus niger in 1869, but it was nearly a century
later that zinc was found to be an essential micronutrient for
humans.2,3 Zinc deﬁciency is a global public health problem,
leaving ~ 2 billion people at risk for deﬁciency of this trace metal.4
Human zinc deﬁciency causes a myriad of symptoms, including
diarrhea, alopecia, immune system impairment, chronic inﬂam-
mation, compromised physical growth and development, neuro-
logical deﬁcits and impaired reproductive development.5–7 In
addition to its important role in normal human physiology, zinc
has been associated with pathophysiological conditions, including
cardiovascular disease, depression, neurodegenerative diseases
such as Alzheimer’s disease, diabetes mellitus and cancer.8
Consistent with its multifaceted roles in human health and
disease, zinc has a number of biological functions at the cellular
level. Since it was ﬁrst discovered as a component of the
erythrocyte enzyme carbonic anhydrase in 1939, zinc has been
identiﬁed as a cofactor in over 300 enzymes spanning all enzyme
classes.9,10 Equally, zinc is found as a structural component of
proteins, and it has been estimated that ~ 3000 proteins, or 10% of
the human proteome, are zinc containing.11 Zinc also serves as a
signaling molecule that mediates a number of cellular signal
transduction processes.12
In this review, we will provide an overview of zinc homeostasis
in humans, emphasizing the role of zinc transporters and recent
developments in the elucidation of their structures. The role of
zinc as a signaling molecule will be discussed. In addition, we will
examine the interplay of zinc transporters and zinc signaling
pathways in several cancer types.
ZINC HOMEOSTASIS
The human body contains about 2 g of zinc, of which only 0.1% is
present in plasma and the remainder is present within the cells.13
In mammalian cells, zinc is in one of two forms: protein-bound
zinc, which includes zinc both tightly and loosely bound to
proteins; and free zinc ions, which are likely not free but are bound
by unknown (non-protein) ligands.14–16 The free zinc concentra-
tion in mammalian cells, while in the picomolar range, likely
represents a physiologically signiﬁcant source of zinc, particularly
regarding its role in signaling.16 The diverse forms of zinc in the
cell make it difﬁcult to assess accurately the intracellular
distribution of zinc. Early macro-analytical studies with fractio-
nated rat liver cells, as well as more recent measurements using
inductively coupled plasma mass spectrometry on fractionated
human lung adenocarcinoma cells, reported that 30–40% of total
intracellular zinc is found in the nucleus, 50% of zinc is in the
cytoplasm and the remaining 10–20% is membrane-associated.17
Nuclear zinc, which is tightly bound to proteins, constitutes the
permanently bound zinc pool and is unlikely to be detectable by
ﬂuorescent indicators, which measure chelatable, or loosely
bound, zinc.18,19 Using a ﬂuorescent indicator and organelle-
speciﬁc dyes, Lu et al.19 demonstrated that free or transiently
bound zinc is found in the endoplasmic reticulum (ER), Golgi
apparatus and mitochondria. Newer micro-analytical techniques
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employing synchrotron X-ray ﬂuorescence chemical imaging allow
detection of both loosely and tightly bound metals with high
spatial resolution and have demonstrated zinc pools in the
nucleus, mitochondria and vesicles.20,21 This intracellular com-
partmentalization of zinc is one of the mechanisms by which cells
maintain zinc homeostasis and zinc regulates cellular functions.
Cellular zinc homeostasis, both total intracellular zinc and
compartmentalized zinc, is tightly controlled by the concerted
action of proteins that transport, sense, store and release zinc.
Zinc transport
Zinc transporters responsible for maintaining cytosolic zinc
concentrations, as well as zinc levels in cellular compartments,
belong to two solute carrier families, SLC30 and SLC39. The human
SLC30, or ZnT, family comprises 10 members (Table 1) that
function to decrease the cytosolic concentration of zinc by
transporting zinc from the cytosol to the extracellular space or into
intracellular compartments. ZnT1 is the only SLC30 member that is
ubiquitously expressed on the plasma membrane and, conse-
quently, plays an important role in regulating cellular zinc
homeostasis.22 Consistent with its essential role, homozygous
Znt1 knockout mice are embryonically lethal.43 The human SLC39,
or ZIP (Zrt-, Irt-like proteins), family comprises 14 members
(Table 2) that function to increase the cytosolic concentration of
zinc by transporting zinc into the cytosol from the extracellular
space or from intracellular compartments. Currently, there is no
direct structural information available for any full-length, human
ZnT or ZIP transporter. However, the X-ray crystal and cryoelectron
microscopy structures of a bacterial ZnT homolog, YiiP, as well as a
structural model of the human ZIP4 and structural information on
the extracellular and intracellular domains of ZIP4 provide
valuable mechanistic insight into zinc transport by these two
families.77–82
X-ray crystal and cryoelectron microscopy structures of the
bacterial ZnT homolog YiiP, a proton:zinc antiporter, reveal an
alternating access mechanism for zinc transport. YiiP functions as
a physiological homodimer, and each protomer consists of six
transmembrane (TM) helices, with TMs 1, 2, 4 and 5 forming a
helical bundle (Figure 1).77–79 Within the helical bundle, a zinc ion
is tetrahedrally coordinated by three highly conserved aspartic
acid residues and one highly conserved histidine in TM2 and
TM5.77 Mutagenesis experiments demonstrated the important role
of this conserved DD–HD zinc-binding site for transport function
and metal selectivity.77,83,84 The YiiP structures differ in the
orientation of the helical bundle with the cryo-EM structure
representing the inward-facing conformation and the X-ray crystal
structure representing the outward-facing conformation of the
transporter.77–79 Conformational switching is due to reorientation
of TM5 that is triggered by zinc binding.85 The bacterial YiiP
structures provide a model for zinc transport by mammalian ZnT
proteins. Mammalian ZnTs are predicted to function as metal:
proton exchangers, are predicted to have six TM helices and have
a signature metal-binding site in TM2 and TM5, similar to the DD–
HD site in the bacterial proteins.86,87 The HD–HD motif is
responsible for the zinc speciﬁcity of ZnTs, as the bacterial DD–
Table 1. Human ZnT proteins
Protein Major location of protein expression Subcellular localization
ZnT1 Ubiquitous Plasma membrane22
ZnT2 Mammary gland, pancreas, prostate, retina, intestine, kidney23–27 Endosome, lysosome, secretory vesicle, plasma membrane23,24
ZnT3 Brain, pancreas, testis28,29 Synaptic vesicles30
ZnT4 Mammary gland, placenta, prostate, kidney, brain25,26,31–34 Endosome, secretory vesicle, plasma membrane26,31
ZnT5 Heart, placenta, prostate, ovary, testis, intestine, thymus, bone25,32,35 Golgi, vesicles, plasma membrane36
ZnT6 Brain, lung, intestine34,37 Golgi, vesicles37
ZnT7 Intestine, stomach, pancreas, prostate, placenta, testis, retina, muscle25,32,38 Golgi, vesicles38
ZnT8 Pancreas, adrenal gland, thyroid, testis39,40 Secretory granule39
ZnT9 Brain, muscle, kidney41 ER41
ZnT10 Brain, retina, liver42 Golgi, plasma membrane42
Table 2. Human ZIP proteins
Protein Sub-
family
Major location of protein expression Subcellular localization
ZIP1 ZIPII Prostate, small intestine, kidney, liver, pancreatic α cells29,44–46 Plasma membrane, ER46,47
ZIP2 ZIPII Prostate, uterine, epithelial cells, ovary liver, skin48,49 Plasma membrane50,51
ZIP3 ZIPII Testes, pancreatic cells52 Plasma membrane53
ZIP4 LIV-1 Small intestine, stomach, colon, cecum, kidney, pancreatic β
cells29,54
Plasma membrane55
ZIP5 LIV-1 Liver, kidney, spleen colon, pancreas56 Plasma membrane56
ZIP6 LIV-1 Testis, pancreatic β cells57,58 Plasma membrane57
ZIP7 LIV-1 Brain, liver, pancreatic β cells58,59 Golgi, ER60
ZIP8 LIV-1 Pancreas, placenta, lung, liver, testis, thymus, red blood
cells57,61,62
Plasma membrane, lysosome, endosomes61
ZIP9 ZIPI Prostate63 Golgi64
ZIP10 LIV-1 Testis, kidney, breast, pancreatic α cells, red
blood cells29,57,62,65,66
Plasma membrane57,67
ZIP11 gufA Mammary gland, testis, stomach, ileum and cecum68,69 Golgi68
ZIP12 LIV-1 Neurons, endothelial, smooth muscle and interstitial cells70,71 Unknown
ZIP13 LIV-1 Retinal pigment epithelial cell line, osteoblasts27,72 ER73
ZIP14 LIV-1 Liver, heart, placenta, lung, brain, pancreatic α cells29,74 Plasma membrane, mitochondria, endosome,
lysosome75,76
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HD site allows for zinc and cadmium transport and the ND–HD site
in ZnT10 confers manganese speciﬁcity.84,88
In addition to the TM domain with its zinc coordination site, the
bacterial YiiP structures have two large C-terminal intracellular
domains (one from each protomer), which, along with two
intracellular loops, establish the primary dimerization contact.77,78
Human ZnTs are similarly predicted to have large C-terminal
cytoplasmic domains, and the C-terminal domain is involved in
dimerization for human ZnTs.89 ZnT3 and ZnT4 form homodimers
via covalent bonds between two tyrosine residues (Y357 and Y372
in ZnT3) in their C-terminal domains, and a YX(XX)(E/D) motif is
likely required for dimerization.89 Human ZnT1–5, all of which
possess the YX(XX)(E/D) motif, form homodimers; whereas ZnT6,
which has several C-terminal tyrosine residues but lacks the YX
(XX)(E/D) motif, only forms a heterodimer with ZnT5.89–92 ZnT1–4
are also capable of forming heterodimers.91 ZnT dimerization is
likely required for proper targeting of the transporter to its cellular
location and for zinc transport activity.89 Molecular modeling of
human ZnT3 based on the bacterial structures revealed that
dimerization via dityrosine bond formation generates zinc-binding
sites that create a putative zinc translocation pathway through the
protein.89 In the bacterial YiiP structure, a binuclear zinc-binding
site was observed in the C-terminal domain and has coordinating
ligands contributed by both protomers.77,78 The similarity
between the YiiP intracellular domain and the βαββαβ
metallochaperone-like fold suggests that the cytoplasmic domain
of ZnTs may be involved in protein-mediated metal transfer.77,93
A third zinc-binding site was identiﬁed in the YiiP intracellular loop
between TM4 and TM5 and may be involved in transfer of the zinc
ion to the membrane zinc-binding site or may function in zinc
sensing.77,78
Figure 1. Structural basis for zinc transport by ZnT and ZIP proteins. (a) Crystal structure of bacterial ZnT homolog showing zinc (red spheres)
bound in the intracellular domain, the membrane interface and TM domain. TM2 (purple) and TM5 (blue) are involved in zinc ion
coordination.78 (b) Crystal structure of mammalian ZIP4 N-terminal ectodomain.81 (c) Structural model of human ZIP4 TM domain.80 TMs 2, 4,
5 and 7 are located in the center of each monomer, and TM4 (purple) and TM5 (blue) contain conserved histidine and aspartic acid residues
predicted to coordinate zinc.
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Compared to ZnTs, less structural and biochemical information
is known about the ZIP family of metal transporters. ZIP family
members show a higher diversity, compared to the ZnT family,
with respect to metal speciﬁcity, transport of zinc, iron,
manganese, copper and cadmium.80,94–96 The energy source for
metal translocation by ZIP proteins, while not driven by ATP
hydrolysis, remains elusive, and several driving forces, including
bicarbonate, pH dependence or phosphorylation, have been
proposed.48,95–98 Further, a bacterial ZIP protein reconstituted in
proteoliposomes was shown to mediate non-saturable and
electrogenic zinc ﬂux, suggestive of zinc channel activity.99 This
observation led Lin et al.99 to speculate that ZIP proteins may
function as channels, rather than transporters, and the downhill
concentration gradient driving zinc inﬂux into the cytosol through
ZIP channels is sustained by cellular homeostasis.
The 14 human ZIP family members are classiﬁed into four
subfamilies (Table 2): ZIPI (with members ZIP1, ZIP2 and ZIP3), ZIPII
(with member ZIP9), gufA (with member ZIP11) and LIV-1 (with
members ZIP4–8, ZIP10 and ZIP12–14).50 All ZIP members are
predicted to have eight TM segments, and members of the LIV-I
family, with the exception of ZIP13, are predicted to have a large,
extracytosolic N-terminal domain. Recently, the N-terminal
domain of a ZIP4 protein was solved using X-ray crystallography.
Human ZIP4 is expressed in the gastrointestinal tract on the apical
surface of enterocytes and as such is the major zinc transporter
responsible for the uptake of dietary zinc. Mutations in ZIP4 cause
the inherited zinc deﬁciency disease acrodermatitis enteropathica
(AE).55,100 AE mutations affect the expression, trafﬁcking, uptake
activity or posttranslational processing of ZIP4, and a number of
these mutations map to the N-terminal extracellular
domain.101–103 The N-terminal domain is posttranslationally
cleaved during extended periods of zinc starvation.102 The crystal
structure of the black fruit bat ZIP4 extracellular domain revealed a
homodimer with two subdomains (Figure 1).81 The dimer core,
comprising the C-terminal subdomain, forms two helix-turn-helix
folds and contains the PAL sequence that is highly conserved
among the LIV-1 subfamily.81 The second subdomain, comprising
the N-terminal residues, has a unique α-helical fold.81 Both
subdomains were shown to be required for optimal zinc transport
activity. The subdomains are connected by a disordered linker
region that is important for proper folding and trafﬁcking of the
full-length ZIP4 protein, as well as for zinc transport.81 Analysis of
the N-terminal ectodomains of the other LIV-1 family members
revealed that the dimerization subdomain is conserved, with the
exception of ZIP7 and ZIP13.81 The ZIP7 and ZIP13 ectodomain
sequences are the most divergent among SLC39 members, and
the oligomerization status of the ZIP7 and ZIP13 ectodomains is
unknown. As the full-length ZIP7 and ZIP13 proteins form
homodimers in the membrane, oligomerization of SLC39 proteins
is not mediated exclusively by their ectodomains.73,98 The ZIP5
ectodomain has also been puriﬁed and shown to be
homodimeric.104 Interestingly, ZIP5, as well as ZIP6 and ZIP10,
colocalize with the prion protein.104,105 An evolutionary link
between ZIP ectodomains and the prion protein has been
suggested but the functional and structural signiﬁcance remains
to be elucidated.106 It has been hypothesized that the extracellular
domains of ZIP proteins may act as extracellular zinc sensors.81
Although to date, there is no crystallographic or cryo-EM
structural data that encompasses the membrane domain for any
ZIP protein, a computational model of the human ZIP4 protein
provides clues as to how ZIP proteins function. Using co-evolution
contact predictions and Rosetta ab initio structure prediction,
structural models of the TM domain of ZIP4 were generated
(Figure 1).80 The models exhibit eight TM helices with TMs 2, 4, 5
and 7 forming a helical bundle that contains a putative metal
permeation pathway.80 The putative ZIP4 metal permeation
pathway is lined with highly conserved histidine and aspartic
acid residues, analogous to the transmembrane zinc-binding site
(DD–HD) observed in the crystal structure of the ZnT homolog YiiP
(Figure 1).77,80 In support of the model’s proposed zinc transloca-
tion pathway, the transport kinetics and metal speciﬁcity of ZIP4
are altered upon mutagenesis of the conserved histidine residues
H507 in TM4 and H536, the ﬁrst histidine in the conserved HEXXH
motif in TM5.80 Equally, ZIP8 and ZIP14 have a variation of the
HEXXH motif (EEXXH), wherein the glutamic acid substitution is
believed to contribute to the broader metal speciﬁcity of these
SLC39 members.107 In generating the ZIP4 structural models, the
contact predictions could only be satisﬁed when ZIP4 was
modeled as a dimer with TM helices forming the dimer
interface.80 Evidence for homodimerization of other ZIP proteins,
including ZIP2, ZIP7 and ZIP13, as well as a heteromer of ZIP6 and
ZIP10 supports the ZIP4 dimer model.73,98,108,109
The ZIP4 structural modeling did not include the large
cytoplasmic loop between TMs 3 and 4, which is predicted to
be present in all ZIP family members. Studies with the ZIP4 protein
have shown that its plasma membrane surface expression is
regulated by the cytoplasmic loop in a zinc-dependent fashion. As
cytosolic zinc concentrations increase (low micromolar), ZIP4
undergoes endocytosis.110 At higher cytosolic zinc concentrations
(~20 μM), ZIP4 is ubiquitinated at a conserved lysine residue
located on the TM3–TM4 loop and is subjected to proteasomal
degradation.111 Further studies using the puriﬁed protein region
have conﬁrmed that the loop directly binds two zinc ions
sequentially.82 The ﬁrst zinc is tightly coordinated by a CysHis3
site, and the second zinc ion binds with lower afﬁnity to a
histidine-only site.82 The TM3–TM4 loop is an intrinsically
disordered region (IDR) that remains disordered upon zinc
binding.82 The structural ﬂexibility of intrinsically disordered
proteins and IDRs provides a functional advantage by permitting
multiple posttranslational modiﬁcations, such as phosphorylation
and ubiquitination, and interactions with multiple protein partners
or ligands.112,113 Disordered protein regions tend not to be under
strong evolutionary conservation.114 Unsurprisingly, the length
and amino-acid sequence of the TM3–TM4 loop is not conserved
among ZIP proteins, but all contain a variable number of potential
zinc-coordinating residues histidine, cysteine, aspartate and
glutamate. Accordingly, the large cytoplasmic loop of ZIP
transporters likely functions as a protein-speciﬁc regulatory region
that senses and responds to cytosolic zinc concentrations. The
speciﬁc protein(s) or ligand(s) interacting with this region have yet
to be identiﬁed and are likely to be important for our further
understanding of ZIP structure–function relationship.
Intracellular zinc sensing
The metal-response element-binding transcription factor (MTF-1)
regulates expression of its target genes in a zinc-dependent
manner and thus acts as a cellular zinc sensor.115,116 MTF-1
interacts with metal-response element (MRE) sequences in the
promoters of zinc-regulated genes.116 MTF-1 contains six Cys2-His2
zinc ﬁngers and three transcriptional activation domains.116 In
response to zinc, MTF-1 is translocated to the nucleus, where it
interacts with MREs and activates transcription of its target
genes.115,116 Transcription of genes encoding metallothioneins
and the zinc efﬂux transporters ZnT1 and ZnT2 are activated by
MTF-1 in response to zinc.24,115,116 Recently, the zinc-
responsiveness of the human transcriptome was examined when
MTF-1 was knocked down relative to normal levels.117 Surprisingly,
almost 200 genes are differentially expressed in response to zinc
when MTF-1 is silenced.117 This observation suggests the presence
of multiple levels of zinc sensing within the cell, with MTF-1 acting
as the master zinc sensor that controls intracellular zinc
concentrations via direct effects on gene expression of zinc
transporters and metallothioneins.117
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Zinc storage and release
Metallothioneins are small, cysteine-rich, metal-binding proteins
that maintain metal homeostasis by acting as metallochaperones.
Metallothioneins have been shown to act as metal donors and
acceptors for metal-containing enzymes and transcription
factors.118,119 Humans possess four metallothionein isoforms
(MT1, MT2, MT3 and MT4) that can maximally bind seven zinc
ions via tetrahedral coordination to cysteine residues. The seven
zinc ions have been shown, based on structural data, to cluster
into two domains, the N-terminal β-domain containing three
metal ions and the C-terminal α-domain containing four metal
ions. Each zinc-binding site possesses an independent zinc-
binding afﬁnity.120 Thus, metallothioneins are capable of buffering
zinc under physiological conditions and controlling the storage
and release of intracellular zinc.
ZINC SIGNALING
In addition to its structural and functional roles in proteins, zinc
acts as a signaling molecule within cells. Early evidence showing
zinc-dependent regulatory effects on protein tyrosine phospha-
tases and transcription factors pointed to the role of zinc in
intracellular signaling pathways.121,122 However, the work of
Yamasaki et al.123 a decade ago established zinc as a second
messenger, whereby changes in its intracellular concentration are
directly altered by an external stimulus and relayed to an
intracellular signaling axis. Using mast cells, Yamasaki et al.123
demonstrated that, upon extracellular stimulation of the IgE
receptor, zinc is rapidly released into the cytosol from an
intracellular store likely originating from the perinuclear and ER
regions. The released zinc, termed the ‘zinc wave’, activates two
mitogen-activated protein kinase (MAPK) pathways, the extra-
cellular signal-related kinase (ERK) and the c-Jun N-terminal kinase
(JNK). MAPKs, such as ERK and JNK, are serine/threonine protein
kinases that, upon activation by extracellular or intracellular
signals, phosphorylate proteins involved in regulating cell
proliferation, differentiation and apoptosis.124 In addition to
activating MAPK signaling cascades, the intracellular zinc released
in the mast cell cytosol inhibits protein tyrosine phosphatase
activity.123 Protein tyrosine phosphatases, which dephosphorylate
tyrosine residues, are involved in many cell signaling cascades,
including the integrin and cadherin signaling pathways that
control cell adhesion and motility.125 The inhibition of protein
tyrosine phosphatases by zinc ions occurs at picomolar concen-
trations of zinc, consistent with cytoplasmic ﬂuctuations of free
zinc levels.126 Tyrosine phosphorylation via protein tyrosine
kinases is also a key component of the cytoplasmic accumulation
of zinc that occurred in leukocytes treated with the extracellular
stimulus lipopoylsaccharide.127 Lipopolysaccharide produces a
rapid increase in cytosolic zinc in mammalian leukocytes, and
the zinc wave inﬂuences signaling pathways involving MAPKs and
the transcription factor NF-κB, which targets genes involved in
cellular development, growth and apoptosis.18
The zinc wave induced by extracellular stimuli in both mast cells
and leukocytes occurred rapidly (within minutes) and originated
from intracellular zinc stores.123,127 This phenomenon has been
termed ‘early’ zinc signaling.128 In addition to its role as a second
messenger in ‘early’ zinc signaling events, zinc has been shown to
participate in ‘late’ signaling events that occur hours after
stimulation and involve zinc transporters.128 One such ‘late’
signaling event was observed during the embryonic development
of zebraﬁsh, during which signal transducer and activator of
transcription (STAT) proteins are active.129 STAT proteins are
activated via a signal transduction pathway that is stimulated by
extracellular binding of cytokines or growth factors to a receptor.
Once activated, STAT proteins transcriptionally regulate a number
of genes. In the zebraﬁsh, STAT3 was shown to stimulate
transcription of the zinc importer ZIP6. The STAT3-dependent
ZIP6 expression results in downstream activation of the transcrip-
tional repressor Snail, which is involved in the epithelial to
mesenchymal transition (EMT) in embryonic development.129,130
Although the function of ZIP6 in zinc uptake during zebraﬁsh
embryonic development was not demonstrated, this study
provided the ﬁrst evidence showing a metal homeostatic
mechanism (ZIP6 transporter) is regulated by signal transduction
(STAT signaling), and the altered cellular metal homeostasis
signals changes in cellular processes. Expression of the zinc
exporter ZnT2 has also been shown to be regulated by a STAT
signaling pathway, and ZnT2 transcription is stimulated by
STAT5.24,131
Another zinc transporter, ZIP14, was shown to be involved in a
G-protein-coupled receptor (GPCR) cAMP signaling pathway using
ZIP14 knockout mice, which displayed growth defects.132 The
growth defects observed in the ZIP14-deletion mice resulted from
inactivation of the parathyroid hormone-related peptide (PTHrP)
signaling pathway that involves cAMP. PTHrP activates adenylyl
cyclase, which increases cAMP levels. cAMP then stimulates
protein kinase A (PKA), resulting in PKA translocation to the
nucleus and activation of the cAMP response element-binding
(CREB) transcription factor by phosphorylation. Phosphorylated
CREB (p-CREB) promotes transcription of c-fos, another transcrip-
tion factor whose target genes are involved in cell differentiation,
proliferation, survival and EMT. This signaling pathway is disrupted
in the ZIP14 knockout mice, which show decreased nuclear
translocation of PKA, a downregulation of p-CREB and lower cAMP
levels.132 The decreased levels of cAMP are due, not to a decrease
in the hormone PTHrP, but to increased activity of phosphodies-
terase (PDE). PDEs are known regulators of GPCR signaling
pathways. Signiﬁcantly lower intracellular zinc levels were
measured in growth plates from the ZIP14 knockout mice than
in ZIP14-expressing mice, demonstrating that ZIP14 is required for
zinc uptake and establishing a link between zinc and GPCR/cAMP-
dependent signaling cascades.132
Expanding the list of signaling cascades inﬂuenced by zinc,
cellular zinc status directly affects the activity of the STAT
pathway.133 STAT proteins regulate the expression of genes
involved in cell proliferation, differentiation, survival and
apoptosis.134 The STAT signaling pathway begins with an
extracellular signal that activates the Janus tyrosine kinase, which
then activates STAT proteins by phosphorylation. Phosphorylated
STAT proteins are translocated to the nucleus where downstream
signals are regulated transcriptionally. Levels of phosphorylated
STAT1 and STAT3 are 40–50% lower, and corresponding nuclear
levels of these STAT proteins are lower, in fetal rat brains upon
maternal zinc deﬁciency compared to the zinc-adequate
controls.133 Equally, cytosolic zinc accumulation in lactating ZnT2
knockout mice resulted in a signiﬁcant reduction in phosphory-
lated STAT5 levels, but not total STAT5 levels, compared to mice
expressing ZnT2.135 As zinc has been shown to inﬂuence many
phosphorylation-dependent signaling cascades (for example,
MAPKs, protein tyrosine phosphatases and transcription factors)
that play important roles in cell development, proliferation and
cell death, proper maintenance of cellular zinc homeostasis is
critical. The dysregulation of cellular zinc homeostasis and its
detrimental effects on intracellular signaling have many patho-
physiological consequences.
Compared to the best-studied metal second messenger
calcium, a more comprehensive picture of zinc cellular signaling
remains elusive. Technological advancement in zinc measurement
and regulation, as well as more systematic signaling studies are
critical in making progress in these areas. In the following section,
the consequences of zinc dyshomeostasis on zinc signaling in
cancer will be discussed.
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ZINC TRANSPORTERS AND ZINC SIGNALING IN CANCER
Cellular zinc homeostasis is altered in cancer. Zinc levels in serum
are typically decreased in patients with tumors, including breast,
head and neck, lung, liver, prostate, pancreatic and gynecological
tumors, compared to normal serum levels.136 However, while
serum zinc levels are low in most cancers, studies measuring zinc
levels in tumor and/or tumor peripheral tissues in different solid
cancer types are inconsistent, reporting elevated, decreased or no
change in zinc levels when compared with the corresponding
normal tissues.136 Although the mechanism and effects of zinc
dyshomeostasis on cancer initiation and progression are not fully
deﬁned, some studies have reported changes in zinc transporter
status and effects of altered zinc levels on signaling pathways in
tumor tissues and cancer cell lines. The most extensive studies on
zinc homeostasis and zinc signaling in cancer have focused on
pancreatic, prostate and breast tumors.
Pancreatic cancer
The pancreas, a gland adjacent to the stomach, has two distinct
functionalities as an endocrine and an exocrine gland, and proper
pancreatic function requires physiological zinc homeostatic
mechanisms. As an endocrine gland, the pancreatic islet cells,
which include α, β and δ cells, contribute to blood glucose levels
and insulin production. The α cells secrete the hormone glucagon
to control hypoglycemia, and zinc acts as a signaling molecule for
glucagon secretion. The zinc importers ZIP1, ZIP10 and ZIP14 are
expressed on the plasma membrane of pancreatic α cells.29
Pancreatic β cells produce a zinc:insulin complex that is stored in
zinc-rich secretory granules.39 ZIP4 is expressed on the plasma
membrane of pancreatic β cells, suggesting that ZIP4 contributes
to maintaining adequate zinc levels in the β cells for insulin
secretion.29 ZIP6 and ZIP7 have also been shown to be expressed
in human β cells.58 Decreasing the expression level of ZIP6 and
ZIP7 changed the uptake of zinc into β cells and decreased insulin
secretion. In addition, the zinc exporter ZnT8 transports zinc into
the β-cell granules, providing zinc for the zinc:insulin complex.39
As an exocrine gland, pancreatic acinar cells generate digestive
enzymes, many of which are zinc-dependent, in zymogen
granules. The SLC30 member ZnT2 transports zinc from the
cytosol into the zymogen granules.24 The zinc importer ZIP5 is
expressed on the plasma membrane of the acinar cells.137
Pancreatic cancer is ranked as the fourth leading cause of death
due to cancer, and one- and ﬁve-year survival rates are 20 and 7%,
respectively. Dysregulation of cellular zinc homeostasis has been
implicated in the progression of pancreatic cancer. Early studies
identiﬁed increased mRNA levels of the zinc transporter ZIP4 in 16
of 17 human pancreatic adenocarcinoma samples compared to
normal pancreatic tissue.138 Equally, in mouse models, ZIP4-
expressing xenografts yield larger tumors and increased cell
proliferation compared to negative controls.138 ZIP4 localizes to
the basolateral membrane of pancreatic β cells, and its upregula-
tion in pancreatic tumors would presumably increase cellular zinc
levels.138,139 However, using zinc-sensitive histochemical staining,
Costello et al.140 measured lower zinc levels in human pancreatic
cancer tissues spanning early to late malignant stages compared
to normal tissues. Concurrent with the decreased zinc levels, ZIP3
is downregulated in the pancreatic cancer tissues, but ZIP4 levels
were not quantiﬁed.140 In a comparative study of the mRNA levels
of all ZIP and ZnT transporters in human pancreatic cancer and
normal tissues, all ZIP proteins are downregulated in the cancer
tissues with the exception of ZIP4, which is upregulated.141
Similarly, gene expression levels for all ZnT transporters are lower
or unchanged in the pancreatic cancer tumors compared to
normal tissues.141 Although the data are consistent with the
previously observed downregulation of ZIP3 and upregulation of
ZIP4, it is difﬁcult to reconcile how increases in zinc transporter
mRNA levels result in the decreased cellular zinc levels observed in
pancreatic cancer tissues. It should be noted that, to date, there
has been no comprehensive study comparing cellular zinc
concentrations and zinc transporter expression in the same tissue
samples. High variability in zinc transporter expression has been
observed in different pancreatic cancer tissues and cell lines.141
Equally, mRNA levels and protein expression do not necessarily
correlate as many zinc transporters, including ZIP4, are regulated
by posttranslational mechanisms.142 Moreover, as ZIP4 has been
shown to transport other metals, including iron and copper, it
remains to be determined whether the observed increase in ZIP4
expression in pancreatic cancer alters cellular zinc concentrations
or alters the cellular homeostasis of another metal.80,94 For
example, serum copper levels are higher in patients with
pancreatic cancer, and copper has been shown to have tumor-
promoting activity in cells.143–146
Prostate cancer
The human prostate gland contains exceptionally high levels of
zinc (~800–1500 μM in prostate epithelial cells compared to
~ 100–500 μM in other soft tissue cells), and the zinc concentra-
tion in prostatic ﬂuid is about 500-fold greater than in plasma.147
Also, the mitochondrial zinc level in prostate cells is higher than in
other cell types.147 Zinc accumulation in prostate epithelial cells is
responsible for their unique metabolic and energetic status as
‘citrate producing’, ‘low respiring’ cells.147 Zinc disrupts both the
Kreb’s cycle, by inhibiting m-aconitase, which converts citrate to
cis-aconitate resulting in citrate accumulation, and mitochondrial
electron transport, likely via inhibition of cytochrome c reductase.
Zinc accumulation in prostate epithelial cells is attributed to the
expression of ZIP1, which is present on the basolateral membrane
and functions as the major importer of zinc from circulating blood
plasma into prostate cells.44,148 In addition to ZIP1, ZIP2 and ZIP3
have been identiﬁed on the apical surface of normal prostate cells,
and it is speculated that these proteins function in the reuptake of
zinc from the prostatic ﬂuid.149
Compared with normal or nonmalignant prostate tissue,
malignant prostate tissue displays markedly lower levels of zinc,
and the decline in zinc occurs early in the malignant
transformation.150 Concomitant with the declining zinc levels,
ZIP1 gene expression is downregulated in prostate cancer.151
Other ZIP family members, ZIP2, ZIP3 and ZIP4, also show reduced
expression in prostate cancer cells.149,152 In addition, ZIP3 localizes
to lysosomal membranes in a prostate cancer cell line compared
to its plasma membrane localization in normal cells.148 Changes in
the expression levels of the zinc efﬂux transporters ZnTs during
prostate tumorigenesis are ambiguous. ZnT1 expression has been
reported to be decreased, increased or unchanged, ZnT4 is
decreased or unchanged, ZnT10 is increased and ZnT5 and ZnT6
are decreased in prostate cancer tissues and cell lines compared
to normal or nonmalignant prostate tissue.153–157 Although it is
unclear what role ZnTs play in prostate cancer, the important role
of ZIP1 in normal prostate epithelial cells and in prostate cancer
development led to the designation of ZIP1 as a tumor suppressor
gene in the prostate gland.150 As prostate cancer cell lines
constitutively express ZIP1, as well as other zinc transporters, it is
hypothesized that the downregulation of zinc transporters in
malignant prostate tissue is due to epigenetic silencing.150
The reduced zinc levels in prostate tumors caused by decreased
ZIP transporter expression alter intracellular zinc signaling path-
ways leading to tumor-promoting activities. Zinc status affects
signaling via the Akt protein (protein kinase B) in malignant
prostate cells (Figure 2).158 Zinc-deﬁcient prostate cancer cells
accumulate phosphorylated Akt (p-Akt) due to the absence of the
phosphatase and tensin homolog (PTEN) protein. PTEN is known
to be inactivated by genomic deletion or rearrangements in the
early stages of prostate cancer oncogenesis.159,160 Normally, PTEN
negatively regulates phosphoinositide 3-kinase (PI3K) activity. In
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the absence of PTEN, PI3K phosphorylates Akt, and p-Akt
subsequently phosphorylates the cyclin-dependent kinase inhibi-
tor p21.158 Phosphorylated p21 is retained in the cytoplasm,
affecting cell cycle regulation likely due to downstream effects on
the cyclin D/cyclin-dependent kinase 4 (CDK4) complex and the
proliferating cell nuclear antigen (PCNA). Thus, an Akt-p21
signaling pathway promotes cell proliferation in prostate cancer
cells, and this pathway depends on the absence of the zinc
transporter ZIP1 and PTEN. PTEN also interacts with MTF-1, linking
PTEN activity to the regulation of MTF-1 target genes, such as
metallothioneins.161 Metallothioneins, particularly MT1 and MT2,
are downregulated in prostate cancer tissues compared to normal
prostate tissue.162,163 Moreover, the levels of metallothionein in
human prostate cancer tissue inversely correlate with prostate
cancer relapse.163 Accordingly, prostate cancer exhibits a complex
network linking cellular zinc homeostatic mechanisms, including
zinc transporters and metallothioneins, to signaling pathways that
promote tumorigenesis.
Breast cancer
The cellular zinc homeostatic mechanisms in the normal human
mammary gland are not known precisely, and much of what is
known has been elucidated from human models or mouse
studies.164 Zinc plays an important role in normal mammary gland
growth and development and during lactation and post-lactation
transformations (as reviewed by McCormick et al.).164 Normal
mammary epithelial cells express ZIP5 at the cell surface where
ZIP5 is likely involved in metal uptake.164 Other ZIP proteins,
including ZIP3, ZIP7, ZIP11, ZIP12 and ZIP14, are expressed within
intracellular compartments.68 ZnT2 also plays an important role in
mitochondrial zinc transport during normal mammary gland
development.165 During lactation, the mammary gland hyper-
accumulates zinc, particularly in the Golgi apparatus and the
secretory system, to meet increased cellular needs and for
secretion into breast milk.166 ZIP5, ZIP8 and ZIP10 may be
involved in zinc uptake from plasma during lactation.68 Interest-
ingly, ZIP7, which exports zinc from the Golgi apparatus and ER, is
more highly expressed during lactation, suggesting that the zinc
accumulated in the Golgi apparatus is remobilized to the cytosol
during lactation.68 ZnT4 is also located on the Golgi apparatus and
has been suggested to contribute to zinc export into breast milk.31
Zinc secretion into breast milk requires ZnT2, which localizes both
to the endosomal/secretory vesicles and to the plasma
membrane.23 Mutations in ZnT2 cause the disorder transient
neonatal zinc deﬁciency, conﬁrming its essential role in zinc
secretion into breast milk.33,167 ZIP3 may function in reuptake of
zinc from breast milk.168 Finally, post-lactational changes in the
mammary gland involve both lysosomal-mediated cell death and
mitochondrial-mediated apoptosis.164 The zinc requirements for
these processes may rely on changes in ZnT2, ZnT4 or ZIP8
localization as these proteins have been shown to localize to
lysosomal compartments in other cell types.31,164,169,170 Given the
importance of zinc homeostasis in the mammary gland, it has
been suggested that nutritional zinc status may be a risk factor for
breast cancer.164,171 In support of this, the incidence of mammary
tumors in primiparous mice exposed to a carcinogen is lower in
mice fed a zinc adequate diet than in mice fed a marginally zinc-
deﬁcient diet, similar to the zinc-deﬁcient diets often consumed
by humans.172
In contrast to most solid tumors, breast cancer tissues show
signiﬁcantly higher zinc levels compared with normal breast
tissue.136,173–176 Zinc distribution and zinc transporter levels show
distinct proﬁles in breast cancer subtypes.142 Breast cancer is
classiﬁed into basal (or triple negative), human epidermal growth
factor receptor 2 (HER2) overexpression and luminal (or estrogen
receptor positive, ER+) A (low-grade) and B (high-grade) tumors.
Using X-ray ﬂuorescence microscopy, Chandler et al.142 observed
high zinc accumulation around the margins of luminal tumors,
whereas basal tumors show uniform distribution of zinc. Breast
tumor tissues were analyzed for gene expression of metallothio-
neins and zinc transporters (ZIP and ZnT). Compared to luminal
(ER+) and HER2 overexpression tumors, basal breast cancer
tumors expressed higher levels of metallothioneins, ZIP4 and
ZIP14 genes and lower levels of ZIP6, ZIP9 and ZIP11.142 Luminal
breast cancer tumors express higher levels of the ZIP6 gene
compared to basal and HER2 overexpression tumors, and ZIP8
gene expression is greater in high-grade versus low-grade ER+
tumors.142 Similarly, gene and protein expression proﬁles for zinc
transporters have been assessed in luminal and basal breast
cancer cell lines. Kagara et al.66 observed higher gene expression
of ZIP10 in basal cells and higher gene expression of ZIP6 in
luminal cells. At the protein level, basal cells display higher levels
of ZnT1, ZIP1 and ZIP10 compared to normal cells; luminal cells
display higher levels of all ZnT proteins ZIP3, ZIP5, ZIP6, ZIP8 and
ZIP10.142 It has been suggested that the differing zinc transporter
proﬁles and their effects on cellular zinc homeostasis may
contribute to the phenotypic differences, including invasiveness,
metastasis and treatment effectiveness, in breast cancer
subtypes.142
ZIP10 and ZIP6 have been linked to tumor migration in both
basal and luminal breast cancers.66,109,177 In basal breast cancer
cells, ZIP10 functions as a zinc importer, and ZIP10-mediated zinc
uptake stimulates cell migration.66 Similarly, in luminal breast
cancer cells, ZIP10 promotes cell migration.109 Further, in luminal
breast cancer cells, ZIP10 has been shown to form a heteromer
with ZIP6.109 In both ZIP10- and ZIP6-expressing luminal breast
cancer cells, the glycogen synthase kinase signaling pathway is
inhibited, leading to activation of the Snail transcription factor that
represses genes for cell adhesion and promotes EMT
(Figure 3).109,177 ZIP6, whose gene expression is induced by STAT3
and in the absence of ZIP10, was observed to undergo cleavage of
its N-terminal domain, which alters its cellular localization from the
ER to the plasma membrane.109,177 As both ZIP6 and ZIP10, along
with ZIP5, have a prion-like ectodomain, these data suggest a
relationship between this subclass of LIV-1 transporters and breast
cancer metastasis.
The most common treatment for luminal (ER+) breast cancers is
the anti-estrogen drug tamoxifen. However, almost all patients
Figure 2. Zinc deﬁciency in prostate cancer cells promotes cell
survival via a phosphoinositide 3-kinase (PI3K) signaling pathway.
Prostate cancer cells lack ZIP1 and PTEN. In zinc-deﬁcient, PTEN-
deﬁcient conditions, PI3K is stimulated, leading to phosphorylation
of protein kinase B (Akt) via phosphoinositide-dependent kinase
(PDK). p-Akt then phosphorylates the cyclin-dependent kinase
inhibitor p21. Phosphorylated p21 is retained in the cytoplasm
where it may affect the cell cycle activity of the cyclin D/cyclin-
dependent kinase 4 (CDK4) complex. In addition, the lack of nuclear
p21 may prevent activation of the PCNA, which normally prevents
DNA synthesis during cell cycle progression. Thus, zinc deﬁciency
affects p21 signaling pathways, leading to cell proliferation in
prostate cancer cells.
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with metastatic breast cancer and 40% of patients receiving
tamoxifen as an adjuvant therapy experience cancer relapse due
to acquired tamoxifen resistance (TamR).178 An association
between TamR and zinc dyshomeostasis has been identiﬁed
(Figure 3).179 Compared to tamoxifen-sensitive cells, TamR breast
cancer cells have twice the level of intracellular zinc and show
increased mRNA and protein expression levels of the LIV-1 zinc
transporter, ZIP7.179 The increased intracellular zinc is a direct
result of the ZIP7 protein, as a decrease in zinc was observed in
TamR cells in which ZIP7 was silenced.179 ZIP7, which localizes to
the Golgi and ER membranes, is activated by protein kinase CK2
through phosphorylation of serine residues located in the large
cytosolic loop of the transporter.98 The CK2 stimulation of ZIP7
occurs within minutes after exposure to an extracellular stimulus,
suggesting that ZIP7 generates a zinc wave that is transduced to
‘early’ zinc signaling pathways in TamR breast cancer cells.98 In
TamR cells, zinc stimulates MAPKs (ERK1 and ERK2) and Akt,
indicating the involvement of ZIP7-mediated zinc transport in
intracellular signaling pathways that affect cell proliferation, cell
migration and apoptosis.98,179
Similarly, zinc activates the ERK and Akt kinase signaling
pathways in breast cancer cells modeling HER2 overexpression
tumors.180 In the HER2 overexpression cells, ERK and Akt
activation arise from a zinc-dependent stimulation of the G
protein-coupled estrogen receptor (GPER). Following stimulation,
GPER transactivates the receptor tyrosine kinase epidermal growth
factor receptor (EGFR). EGFR phosphorylation leads to down-
stream signaling that stimulates the kinases Erk1, Erk2 and Akt.
Phosphorylated Erk1, Erk2 and Akt are translocated to the nucleus
where they regulate the transcription of genes involved in cell
proliferation, cell cycle progression and migration. The involve-
ment of zinc as a signal for the GPER pathway may have
prognostic effects. Higher GPER expression has been linked to
poor survival in HER2-positive breast cancer cases.181,182
CONCLUSION
Recently, zinc has been recognized as a critical signaling molecule
in normal cell physiology as well as in pathophysiological
conditions, such as cancer. Under normal conditions, zinc has
been shown to regulate several phosphorylation-dependent
signaling cascades, including MAPKs and Akt, that play important
roles in cell development, proliferation and cell death. Many of
these same signaling cascades have been shown to be affected by
zinc levels in cancer and lead to cancer cell proliferation and
metastasis. Zinc signaling is controlled by cellular zinc homeo-
static mechanisms that regulate intracellular zinc concentrations,
especially the two zinc transporter families ZIP and ZnT. Not
surprisingly, altered expression of these transporters is evident in
many cancers. As a deeper understanding of the relationship
between zinc transporter expression and downstream signaling
pathways in tumors is gained, it may become possible to utilize
zinc transporter proﬁles to tailor cancer treatments more
effectively.
The complex interplay between zinc transporters and zinc
signaling is just beginning to be deciphered. More structural
studies on mammalian ZnT and, more importantly, on mammalian
ZIP proteins are needed to clarify better the roles of metal
transporters in cellular zinc homeostasis. One area that remains
unclear is how the zinc signal is relayed from the transporter to
the signaling pathways, many of which also involve membrane
receptors. As very little free zinc exists in the cell, one area that
needs exploration is the identiﬁcation of protein–protein interac-
tions that may be involved in the zinc relay. A detailed
understanding of cellular zinc homeostasis and signaling is not
only vital to understanding the role of zinc in normal cellular
processes, but may also uncover new targets for cancer drug
development.
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Figure 3. ZIP-mediated signaling pathways promote cell prolifera-
tion and metastasis in luminal and tamoxifen-resistant breast cancer
cells. (a) ZIP6/ZIP10-mediated signaling pathway in luminal breast
cancer cells. ZIP6, whose gene expression is induced by STAT3, is
expressed on the ER membrane. On cleavage of its N-terminal
domain, ZIP6 translocates to the plasma membrane. ZIP10 may
undergo the same posttranslational processing leading to plasma
membrane localization. On the plasma membrane, ZIP6 and ZIP10
exist as homo- and heteromers. Zinc uptake via ZIP6 and/or ZIP10
results in the inactivation of glycogen synthase kinase-3β (GSK3β) by
phosphorylation either directly or indirectly by activation (phos-
phorylation) of Akt. Inactive GSK3β is unable to phosphorylate the
transcription factor Snail, resulting in nuclear retention of Snail. Snail
represses transcription of the adhesion molecule E-cadherin, leading
to cell migration and metastasis. (b) ZIP7-mediated signaling
pathway in tamoxifen-resistant breast cancer cells. The signaling
pathway involves stimulation of the EGFR, a receptor tyrosine kinase
that responds to binding of the extracellular ligand by dimerization,
trans-phosphorylation and tyrosine kinase activation. EGFR is also
transactivated by the protein tyrosine kinase Src, and this
transactivation is stimulated by zinc. It is unclear where the zinc
that stimulates Src activates originates, but it may involve a plasma
membrane ZIP transporter. EGFR activation results in phosphoryla-
tion of ZIP7 by the serine/threonine protein kinase CK2, although it
is unclear how the signal is transduced from EGFR to CK2.
Phosphorylated ZIP7 transports zinc from the Golgi or ER into the
cytoplasm. The increased cytoplasmic zinc inhibits protein tyrosine
phosphatases (PTP), causing sustained activation of EGFR and Src. In
addition, the released zinc activates kinases ERK1, ERK2 and Akt,
which regulate signaling pathways leading to cancer cell prolifera-
tion and migration.
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